A WORLD WITHOUT CANCER: WE’RE BRINGING IT CLOSER EVERY DAY
Despite all the advances the oncology community has seen since 1987 when we came to America, there are still too many cancer patients with unmet needs. That’s why, as a human health care company, we keep increasing our commitment to oncology. We won’t stop pursuing breakthroughs until the world is cancer-free. Please visit our clinical trials area for information about open Eisai oncology studies.
NEWS AND BREAKTHROUGHS
Read the latest on how we’re helping people living with cancer.
COULD THE OCEAN HOLD
AN ANSWER TO CANCER?
KNOWLEDGE IS POWER FOR PEOPLE LIVING WITH CANCER. LEARN MORE ABOUT:
HOW DOES OUR hhc
MISSION INSPIRE ONCOLOGY BREAKTHROUGHS? HERE’S A REAL-WORLD EXAMPLE
When we first set out to develop a new anti-cancer agent, we didn’t sacrifice quality for speed. We concentrated on diseases with poor prognoses and few treatment options, regardless of the size of the patient populations. We prioritized how the compound would bind to certain targets implicated in the pathogenesis of the cancer.
Our determination to address patients' unmet medical needs drove us to synthesize a chemical process with millions of steps. Ultimately, it led us to develop a targeted agent.
We're now investigating that agent with Merck (known as MSD outside the United States and Canada) in combination with their anti-PD-1 therapy in different kinds of cancer in the hopes of reaching more patients in need. In fact, Eisai and Merck received two Breakthrough Therapy designations and two approvals from the FDA.
We're evaluating the combination in multiple tumor types in clinical trials across the globe.
- Biliary tract cancer
- Endometrial carcinoma
- Gastric cancer
- Gastroesophageal adenocarcinoma
- Glioblastoma
- Hepatocellular carcinoma
- Non-small cell lung cancer
- Pancreatic cancer
- Renal cell carcinoma
- Squamous cell carcinoma of the head and neck
- Urothelial carcinoma
Learn more about our collaboration here.
Learn more about:
HERE'S WHAT'S NEXT
MISSION ACCEPTED: THE NEXT EVOLUTION OF IMMUNO-ONCOLOGY
To date, “immuno-oncology” has been synonymous with one modality. Eisai’s aim is to show that other modalities — alone, in combination or in sequence with checkpoint inhibitors — may help to normalize or even enhance the immune microenvironment and enhance antitumor activity. This is what our pipeline has been designed to explore.
The same small molecule and translational medicine expertise that served as the foundation for Eisai Oncology's current portfolio is also powering the future of our oncology pipeline. Combined with our Big Data, human biology and cancer genomics capabilities, we are poised to expand immuno-oncology as we know it to usher in a new era of personalized cancer medicines.
OUR PIPELINE LEADS STRAIGHT TO THE FUTURE OF ONCOLOGY
We’re pursuing potential breakthroughs designed to:
- Modulate the microenvironment of a broad range of tumors
- Inhibit signaling pathways that play important roles to inactivate the immune system
- Leverage cancer genomics to target cancer drivers, tumor resistance and immune evasion
ONE TEAM
Looking for a team environment where you’ll be challenged to break through? Join our human health care mission to make a difference in the lives of patients.
H3 Biomedicine (H3B) was established in December 2010 as a subsidiary of Eisai and began operations in August 2011 in the pursuit of two objectives: to both identify and create innovative therapeutic compounds by focusing on drug discovery and development driven by patient-derived genomic information.
Since then, H3B has been a significant and innovative research and development engine. As we look into the future to discover the next novel therapy, Eisai has decided to realign our global discovery centers and several development functions into a global organization focused on Deep Human Biology Learning (DHBL).
With this shift and upon completion of its objectives, H3B has closed. We are grateful to our H3B colleagues for their significant contributions toward advancing science and proficiency in their key fields of expertise.
Going forward, Eisai will continue to focus on new scientific approaches that create unique and competitive drug discovery and development for which our company is known. Our innovations intersect health and technology to help people predict, prevent and treat serious diseases.
To learn more about Eisai’s precision oncology research and development, please visit Eisai Inc. If you have questions or need assistance regarding H3B, its work or assets, please Contact Us.
